Brooklyn ImmunoTherapeutics CSO Kevin D'Amour resigns; separation agreement provides $311K severance

Ernexa Therapeutics Inc.

Dr. Kevin D'Amour's resignation as Chief Scientific Officer effective August 26, 2022.
Separation agreement includes 9 months' base salary totaling $311,250 (less withholdings).
Vested options on 57,296 shares exercisable for 90 days post-separation; all unvested equity forfeited.
COBRA health premium paid for the 9-month severance period.
D'Amour agrees to cooperation, non-disparagement, and a general release of claims.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kevin D'Amour

Chief Scientific Officer

ERNA · Ernexa Therapeutics Inc.

Effective: 2022-08-26
Filed: September 1, 2022, 7:59 PM ET

On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin D'Amour resigned as Chief Scientific Officer at Ernexa Therapeutics Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-031997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.